NCT03657745 Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
| NCT ID | NCT03657745 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alzheimer's Light LLC |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2018-01-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2018-01-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLife https://www.alz.life/) that delivers light therapy at 40 Hz combined with cognitive therapy to improve cognition, function, and quality of life in Alzheimer's disease.
Eligibility Criteria
Inclusion Criteria: * Alzheimer's disease * Cognitive Impairment Exclusion Criteria: * any previously noted epileptic seizures, including febrile seizures. * any significant disease of the eye, such as macular degeneration. Since the 40Hz light therapy is delivered via eye stimulation, healthy eyes are required.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03657745 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03657745 currently recruiting?
Yes, NCT03657745 is actively recruiting participants. Contact the research team at vysha@bu.edu for enrollment information.
Where is the NCT03657745 trial being conducted?
This trial is being conducted at Miami, United States.
Who is sponsoring the NCT03657745 clinical trial?
NCT03657745 is sponsored by Alzheimer's Light LLC. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.